Sébastien Benzekry

List of Publications by Year
in descending order

51	1,490	393982 19	360668 35
papers	citations	h-index	g-index
62	62	62	1813
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Development and Validation of a Prediction Model of Overall Survival in High-Risk Neuroblastoma Using Mechanistic Modeling of Metastasis. JCO Clinical Cancer Informatics, 2021, 5, 81-90.	1.0	12
2	Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression. Molecular Cancer, 2021, 20, 136.	7.9	17
3	Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data. Cancers, 2021, 13, 6210.	1.7	19
4	Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?. JCO Precision Oncology, 2020, 4, 486-491.	1.5	9
5	Artificial Intelligence and Mechanistic Modeling for Clinical Decision Making in Oncology. Clinical Pharmacology and Therapeutics, 2020, 108, 471-486.	2.3	50
6	Machine Learning and Mechanistic Modeling for Prediction of Metastatic Relapse in Early-Stage Breast Cancer. JCO Clinical Cancer Informatics, 2020, 4, 259-274.	1.0	39
7	Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors. PLoS Computational Biology, 2020, 16, e1007178.	1.5	84
8	Title is missing!. , 2020, 16, e1007178.		0
9	Title is missing!. , 2020, 16, e1007178.		0
10	Title is missing!. , 2020, 16, e1007178.		0
11	Title is missing!. , 2020, 16, e1007178.		0
12	Title is missing!. , 2020, 16, e1007178.		0
13	Title is missing!. , 2020, 16, e1007178.		0
14	Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. Anticancer Research, 2019, 39, 3419-3422.	0.5	6
15	Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer. Scientific Reports, 2019, 9, 13018.	1.6	35
16	Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non–Small Cell Lung Cancer. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 577-586.	1.3	8
17	CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies. AAPS Journal, 2019, 21, 50.	2.2	13
18	Population Modeling of Tumor Growth Curves, the Reduced Gompertz Model and Prediction of the Age of a Tumor. Lecture Notes in Computer Science, 2019, , 87-97.	1.0	1

#	Article	IF	Citations
19	Revisiting Bevacizumabâ€‰+â€‰Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Nonâ€“Small Cell Lung Carcinoma. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 42-50.	1.3	17
20	Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1-9.	1.5	21
21	Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology. Critical Reviews in Oncology/Hematology, 2018, 129, 1-12.	2.0	35
22	Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach. Oncotarget, 2018, 9, 2574-2590.	0.8	7
23	Abstract 4264: Mathematical modeling of differential effects of sunitinib on primary tumor and metastatic growth. , 2018, , .		0
24	Mathematical Modeling of Tumorâ€“Tumor Distant Interactions Supports a Systemic Control of Tumor Growth. Cancer Research, 2017, 77, 5183-5193.	0.4	41
25	Non-standard radiotherapy fractionations delay the time to malignant transformation of low-grade gliomas. PLoS ONE, 2017, 12, e0178552.	1.1	20
26	Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis. Oncotarget, 2017, 8, 23087-23098.	0.8	26
27	Abstract 4529: Optimization of the sequence for the administration of bevacizumab in combination with pemetrexed and cisplatin in NSCLC : a pharmacology based in vivo study. , 2017, , .		0
28	Next generation metronomic chemotherapyâ€”report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6â€“8 May 2016, Mumbai. Ecancermedicalscience, 2016, 10, 689.	0.6	10
29	In Vivo Bioluminescence Tomography for Monitoring Breast Tumor Growth and Metastatic Spreading: Comparative Study and Mathematical Modeling. Scientific Reports, 2016, 6, 36173.	1.6	17
30	Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy. Cancer Research, 2016, 76, 4931-4940.	0.4	132
31	Modeling Spontaneous Metastasis following Surgery: An <i>In Vivo-In Silico</i> Approach. Cancer Research, 2016, 76, 535-547.	0.4	73
32	Abstract 2099: Model-riven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice. , 2016, , .		0
33	Abstract 2704: Radiotherapy and immunotherapy in cancer: A mathematical model. , 2016, , .		0
34	Design principles for cancer therapy guided by changes in complexity of protein-protein interaction networks. Biology Direct, 2015, 10, 32.	1.9	26
35	On the growth and dissemination laws in a mathematical model of metastatic growth. ITM Web of Conferences, 2015, 5, 00007.	0.4	0
36	Computational Modelling of Metastasis Development in Renal Cell Carcinoma. PLoS Computational Biology, 2015, 11, e1004626.	1.5	37

#	Article	IF	Citations
37	Host Age Is a Systemic Regulator of Gene Expression Impacting Cancer Progression. Cancer Research, 2015, 75, 1134-1143.	0.4	34
38	Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3453-E3453.	3.3	11
39	Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine. Seminars in Cancer Biology, 2015, 35, 53-61.	4.3	67
40	Capturing the Driving Role of Tumor-Host Crosstalk in a Dynamical Model of Tumor Growth. Bio-protocol, 2015, 5, .	0.2	2
41	Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth. PLoS Computational Biology, 2014, 10, e1003800.	1.5	419
42	Abstract 3677: Model-based optimization of combined antiangiogenic + cytotoxics modalities: application to the bevacizumab-paclitaxel association in breast cancer models. , 2014, , .		3
43	Global Dormancy of Metastases Due to Systemic Inhibition of Angiogenesis. PLoS ONE, 2014, 9, e84249.	1.1	37
44	A Mathematical Model for Growing Metastases on Oncologists' Service. , 2014, , 331-338.		0
45	Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers. Journal of Theoretical Biology, 2013, 335, 235-244.	0.8	45
46	Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice. Journal of Theoretical Biology, 2013, 320, 86-99.	0.8	21
47	Modeling the Impact of Anticancer Agents on Metastatic Spreading. Mathematical Modelling of Natural Phenomena, 2012, 7, 306-336.	0.9	28
48	Passing to the limit 2D–1D in a model for metastatic growth. Journal of Biological Dynamics, 2012, 6, 19-30.	0.8	4
49	Mathematical and numerical analysis of a model for anti-angiogenic therapy in metastatic cancers. ESAIM: Mathematical Modelling and Numerical Analysis, 2012, 46, 207-237.	0.8	14
50	A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology. Comptes Rendus Mathematique, 2012, 350, 23-28.	0.1	23
51	Diffeomorphic Matching and Dynamic Deformable Surfaces in 3d Medical Imaging. Computational Methods in Applied Mathematics, 2010, 10, 235-274.	0.4	16